Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase I/II study of tazemetostat in relapsed or refractory INI1-negative tumors or synovial sarcoma
NL-OMON50516Phase 2Completed
- Sponsor
- Epizyme, Inc.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tazemetostat in malignant rhabdoid tumor (MRT), Atypical teratoid rhabdoid tumor (ATRT), Rhabdoid kidney tumor (RTK) and 3 more (5 arms), sponsored by Epizyme, Inc. Primary endpoints: Dose-limiting toxicities in cycle 1, Recommended phase 2 dose or maximum tolerated dose and 1 more. Started Oct 2017; status: completed.
02
Drugs
tazemetostat
03
Conditions
malignant rhabdoid tumor (MRT)Atypical teratoid rhabdoid tumor (ATRT)Rhabdoid kidney tumor (RTK)Neoplasmsynovial sarcoma (SS)
Beyond the preview
Go deeper on NL-OMON50516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50516.